BASKING RIDGE, N.J., May 29 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, announced today that it will present at the Friedman, Billings, Ramsey & Company 2007 Growth Conference on Wednesday, May 30, 2007 at 3:50 p.m. ET at the Grand Hyatt Hotel in New York City. Daniel Greenleaf, VioQuest’s president and CEO, is scheduled to give an update on the company’s clinical activities. The presentation is scheduled for Room 4 (Plymouth).
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )
A live audio webcast of this presentation can be accessed on the company’s website at http://www.vioquestpharm.com. An audio replay of the presentation will also be available for 60 days after the conference.
About VioQuest Pharmaceuticals
VioQuest Pharmaceuticals, Inc. http://www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which inhibits activation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for Lenocta(TM) for the treatment of leishmaniasis. VioQuest also has recently in-licensed Xyfid(TM), a topical therapy which has shown early clinical promise in the treatment and prevention of chemo-induced hand-foot syndrome, which is expected to be in a Phase II trial in the second half of 2007.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest’s actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest’s planned NDA submission relating to Lenocta(TM) for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize Lenocta(TM) for the treatment of leishmaniasis or any other indication, or that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest’s claims, the possibility that VioQuest’s development efforts relating to its product candidates, including Lenocta(TM), VQD-002 and Xyfid(TM), will not be successful, the inability to obtain regulatory approval of VioQuest’s product candidates, VioQuest’s reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest’s Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Company Contact Daniel Greenleaf, President and Chief Executive Officer 908-766-4400 ext. 115 dan.greenleaf@vioquestpharm.com Edward Bradley, Chief Scientific Officer 908-766-4400 ext. 118 ed.bradley@vioquestpharm.com Brian Lenz, Chief Financial Officer 908-766-4400 ext. 117 brian.lenz@vioquestpharm.com
Photo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGOVioQuest Pharmaceuticals, Inc.
CONTACT: Daniel Greenleaf, President and Chief Executive Officer,+1-908-766-4400 ext. 115, dan.greenleaf@vioquestpharm.com; Edward Bradley,Chief Scientific Officer, +1-908-766-4400 ext. 118,ed.bradley@vioquestpharm.com; Brian Lenz, Chief Financial Officer,+1-908-766-4400 ext. 117, brian.lenz@vioquestpharm.com, all of VioQuestPharmaceuticals
Web site: http://www.vioquestpharm.com/
